Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Reaction Biology
Deal Size : Inapplicable
Deal Type : Inapplicable
New Data at AACR Showcase Reaction Biology's Innovative Approach to Oncology Drug Discovery Services
Details : Adavosertib (AZD1775, MK-1775), a clinical-stage inhibitor of tyrosine kinase WEE1, exhibited a broad anti-cancer activity across all hematological and solid tumor types with IC50 values ranging from 0.06 to 10 µM, matching consistently high expression...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 04, 2022
Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Reaction Biology
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : AstraZeneca | Lustgarten Foundation | Stand Up To Cancer
Deal Size : Inapplicable
Deal Type : Inapplicable
Adavosertib and Gemcitabine in Advanced Pancreatic
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 27, 2022
Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : AstraZeneca | Lustgarten Foundation | Stand Up To Cancer
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 13, 2021
Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 02, 2021
Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of Adavosertib as Treatment for Uterine Serous Carcinoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2020
Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Parexel
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 08, 2020
Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
AZD1775 in Advanced Acute Myeloid Leukemia, Myelodysplastic Syndrome and Myelofibrosis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 24, 2018
Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 12, 2018
Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : AstraZeneca
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Canadian Cancer Clinical Trials Network | BC Cancer Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Prostate Cancer Biomarker Enrichment and Treatment Selection
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 28, 2017
Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Canadian Cancer Clinical Trials Network | BC Cancer Foundation
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Quintiles Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 19, 2017
Lead Product(s) : Adavosertib
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Quintiles Inc
Deal Size : Inapplicable
Deal Type : Inapplicable